Business Description
Pangaea Oncology SA
ISIN : ES0105221008
Share Class Description:
XMAD:PANG: Bearer ShsDescription
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.49 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.32 | |||||
| Debt-to-EBITDA | -3.68 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.07 | |||||
| Beneish M-Score | -2.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.1 | |||||
| 3-Year EPS without NRI Growth Rate | -15.6 | |||||
| 3-Year FCF Growth Rate | 5.4 | |||||
| 3-Year Book Growth Rate | 10.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 56.17 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 23.29 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.5 | |||||
| 9-Day RSI | 35.24 | |||||
| 14-Day RSI | 47.27 | |||||
| 6-1 Month Momentum % | 22.45 | |||||
| 12-1 Month Momentum % | 22.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.34 | |||||
| Quick Ratio | 1.3 | |||||
| Cash Ratio | 0.39 | |||||
| Days Inventory | 479.74 | |||||
| Days Sales Outstanding | 198.1 | |||||
| Days Payable | 2138.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.6 | |||||
| Shareholder Yield % | 3.07 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.93 | |||||
| Operating Margin % | -34.29 | |||||
| Net Margin % | -58.22 | |||||
| FCF Margin % | -33.6 | |||||
| ROE % | -23.12 | |||||
| ROA % | -16.9 | |||||
| ROIC % | -18.51 | |||||
| 3-Year ROIIC % | -26.73 | |||||
| ROC (Joel Greenblatt) % | -96.37 | |||||
| ROCE % | -14.64 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.44 | |||||
| PB Ratio | 2.91 | |||||
| Price-to-Tangible-Book | 28.67 | |||||
| EV-to-EBIT | -18.25 | |||||
| EV-to-Forward-EBIT | -153.85 | |||||
| EV-to-EBITDA | -39.53 | |||||
| EV-to-Revenue | 7.69 | |||||
| EV-to-Forward-Revenue | 4.16 | |||||
| EV-to-FCF | -23.78 | |||||
| Earnings Yield (Greenblatt) % | -5.47 | |||||
| FCF Yield % | -4.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pangaea Oncology SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7.999 | ||
| EPS (TTM) (€) | -0.155 | ||
| Beta | -0.13 | ||
| Volatility % | 21.77 | ||
| 14-Day RSI | 47.27 | ||
| 14-Day ATR (€) | 0.017688 | ||
| 20-Day SMA (€) | 1.766 | ||
| 12-1 Month Momentum % | 22.45 | ||
| 52-Week Range (€) | 1.47 - 1.8 | ||
| Shares Outstanding (Mil) | 34.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pangaea Oncology SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pangaea Oncology SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pangaea Oncology SA Frequently Asked Questions
What is Pangaea Oncology SA(XMAD:PANG)'s stock price today?
The current price of XMAD:PANG is €1.72. The 52 week high of XMAD:PANG is €1.80 and 52 week low is €1.47.
When is next earnings date of Pangaea Oncology SA(XMAD:PANG)?
The next earnings date of Pangaea Oncology SA(XMAD:PANG) is .
Does Pangaea Oncology SA(XMAD:PANG) pay dividends? If so, how much?
Pangaea Oncology SA(XMAD:PANG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers